Associations of ucOC and Other Bone Turnover Markers in Quartiles With Nonfatal and Fatal Myocardial Infarction in Older Men Without Metabolic Syndrome
| Variable . | Range . | MI N (%) . | Univariate HR (95% CI) . | Model 1 HR (95% CI) . | Model 2 HR (95% CI) . | Model 3 HR (95% CI) . | Model 4 HR (95% CI) . |
|---|---|---|---|---|---|---|---|
| OC (μg/L) Q1 | 4.6–14.7 | 32 (7.2) | |||||
| OC (μg/L) Q2–4 | 14.7–143.2 | 152 (9.5) | 1.32 (0.90–1.94) | 1.09 (0.74–1.60) | 1.14 (0.77–1.68) | 1.35 (0.92–2.00) | 1.10 (0.74–1.63) |
| UcOC (μg/L) Q1 | 3.0–8.0 | 34 (7.6) | |||||
| UcOC (μg/L) Q2–4 | 8.1–79.9 | 150 (9.4) | 1.28 (0.88–1.85) | 1.14 (0.79–1.66) | 1.14 (0.79–1.66) | 1.24 (0.85–1.81) | 1.09 (0.75–1.59) |
| ucOC/TOC Q1 | 22.1–49.0 | 66 (12.5) | 1.00 | ||||
| ucOC/TOC Q2–4 | 49.0–87.3 | 118 (7.8) | 0.61 (0.45–0.82) | 0.69 (0.51–0.94) | 0.67 (0.50–0.92) | 0.62 (0.45–0.84) | 0.70 (0.51–0.97) |
| P1NP (μg/L) Q1 | 9.5–28.2 | 30 (6.3) | 1.00 | ||||
| P1NP (μg/liter) Q2–4 | 28.2–710.1 | 154 (9.8) | 1.57 (1.06–2.32) | 1.46 (0.99–2.16) | 1.48 (0.99–2.20) | 1.56 (1.05–2.34) | 1.43 (0.95–2.15) |
| CTX (μg/L) Q1 | 0.1–0.2 | 36 (8.0) | |||||
| CTX (μg/L) Q2—4 | 0.2–2.5 | 148 (9.3) | 1.19 (0.83–1.71) | 1.03 (0.71–1.48) | 1.01 (0.70–1.46) | 1.18 (0.82–1.72) | 0.98 (0.67–1.43) |
| Variable . | Range . | MI N (%) . | Univariate HR (95% CI) . | Model 1 HR (95% CI) . | Model 2 HR (95% CI) . | Model 3 HR (95% CI) . | Model 4 HR (95% CI) . |
|---|---|---|---|---|---|---|---|
| OC (μg/L) Q1 | 4.6–14.7 | 32 (7.2) | |||||
| OC (μg/L) Q2–4 | 14.7–143.2 | 152 (9.5) | 1.32 (0.90–1.94) | 1.09 (0.74–1.60) | 1.14 (0.77–1.68) | 1.35 (0.92–2.00) | 1.10 (0.74–1.63) |
| UcOC (μg/L) Q1 | 3.0–8.0 | 34 (7.6) | |||||
| UcOC (μg/L) Q2–4 | 8.1–79.9 | 150 (9.4) | 1.28 (0.88–1.85) | 1.14 (0.79–1.66) | 1.14 (0.79–1.66) | 1.24 (0.85–1.81) | 1.09 (0.75–1.59) |
| ucOC/TOC Q1 | 22.1–49.0 | 66 (12.5) | 1.00 | ||||
| ucOC/TOC Q2–4 | 49.0–87.3 | 118 (7.8) | 0.61 (0.45–0.82) | 0.69 (0.51–0.94) | 0.67 (0.50–0.92) | 0.62 (0.45–0.84) | 0.70 (0.51–0.97) |
| P1NP (μg/L) Q1 | 9.5–28.2 | 30 (6.3) | 1.00 | ||||
| P1NP (μg/liter) Q2–4 | 28.2–710.1 | 154 (9.8) | 1.57 (1.06–2.32) | 1.46 (0.99–2.16) | 1.48 (0.99–2.20) | 1.56 (1.05–2.34) | 1.43 (0.95–2.15) |
| CTX (μg/L) Q1 | 0.1–0.2 | 36 (8.0) | |||||
| CTX (μg/L) Q2—4 | 0.2–2.5 | 148 (9.3) | 1.19 (0.83–1.71) | 1.03 (0.71–1.48) | 1.01 (0.70–1.46) | 1.18 (0.82–1.72) | 0.98 (0.67–1.43) |
Proportional hazards regression of total OC, ucOC, ucOC/total OC, P1NP, and CTX for the outcome of nonfatal and fatal MI, after excluding men with metabolic syndrome at baseline (n = 1186). Metabolic syndrome was defined according to the National Cholesterol Education Program-Adult Treatment Panel classification as three or more of waist circumference >102 cm, fasting plasma glucose ≥5.6 mmol/liter, or a known diagnosis of diabetes, fasting triglycerides ≥1.7 mmol/liter, fasting high-density lipoprotein cholesterol <1.03 mmol/liter, or blood pressure ≥130/85 mm Hg. Men with a previous diagnosis of hypertension or taking antihypertensive therapy were regarded as fulfilling the criterion for hypertension. Results are shown for men in the highest three quartiles compared with men in the lowest quartile (Q2–4 versus reference Q1).
Model 1: adjusted for age.
Model 2: adjustment as in model 1 and for education, smoking, BMI, and WHR.
Model 3: adjustment as in model 2 and for hypertension, dyslipidemia, diabetes, creatinine, and vitamin D.
Model 4: adjustment as in model 3 and for prevalent CVD and cancer.
Associations of ucOC and Other Bone Turnover Markers in Quartiles With Nonfatal and Fatal Myocardial Infarction in Older Men Without Metabolic Syndrome
| Variable . | Range . | MI N (%) . | Univariate HR (95% CI) . | Model 1 HR (95% CI) . | Model 2 HR (95% CI) . | Model 3 HR (95% CI) . | Model 4 HR (95% CI) . |
|---|---|---|---|---|---|---|---|
| OC (μg/L) Q1 | 4.6–14.7 | 32 (7.2) | |||||
| OC (μg/L) Q2–4 | 14.7–143.2 | 152 (9.5) | 1.32 (0.90–1.94) | 1.09 (0.74–1.60) | 1.14 (0.77–1.68) | 1.35 (0.92–2.00) | 1.10 (0.74–1.63) |
| UcOC (μg/L) Q1 | 3.0–8.0 | 34 (7.6) | |||||
| UcOC (μg/L) Q2–4 | 8.1–79.9 | 150 (9.4) | 1.28 (0.88–1.85) | 1.14 (0.79–1.66) | 1.14 (0.79–1.66) | 1.24 (0.85–1.81) | 1.09 (0.75–1.59) |
| ucOC/TOC Q1 | 22.1–49.0 | 66 (12.5) | 1.00 | ||||
| ucOC/TOC Q2–4 | 49.0–87.3 | 118 (7.8) | 0.61 (0.45–0.82) | 0.69 (0.51–0.94) | 0.67 (0.50–0.92) | 0.62 (0.45–0.84) | 0.70 (0.51–0.97) |
| P1NP (μg/L) Q1 | 9.5–28.2 | 30 (6.3) | 1.00 | ||||
| P1NP (μg/liter) Q2–4 | 28.2–710.1 | 154 (9.8) | 1.57 (1.06–2.32) | 1.46 (0.99–2.16) | 1.48 (0.99–2.20) | 1.56 (1.05–2.34) | 1.43 (0.95–2.15) |
| CTX (μg/L) Q1 | 0.1–0.2 | 36 (8.0) | |||||
| CTX (μg/L) Q2—4 | 0.2–2.5 | 148 (9.3) | 1.19 (0.83–1.71) | 1.03 (0.71–1.48) | 1.01 (0.70–1.46) | 1.18 (0.82–1.72) | 0.98 (0.67–1.43) |
| Variable . | Range . | MI N (%) . | Univariate HR (95% CI) . | Model 1 HR (95% CI) . | Model 2 HR (95% CI) . | Model 3 HR (95% CI) . | Model 4 HR (95% CI) . |
|---|---|---|---|---|---|---|---|
| OC (μg/L) Q1 | 4.6–14.7 | 32 (7.2) | |||||
| OC (μg/L) Q2–4 | 14.7–143.2 | 152 (9.5) | 1.32 (0.90–1.94) | 1.09 (0.74–1.60) | 1.14 (0.77–1.68) | 1.35 (0.92–2.00) | 1.10 (0.74–1.63) |
| UcOC (μg/L) Q1 | 3.0–8.0 | 34 (7.6) | |||||
| UcOC (μg/L) Q2–4 | 8.1–79.9 | 150 (9.4) | 1.28 (0.88–1.85) | 1.14 (0.79–1.66) | 1.14 (0.79–1.66) | 1.24 (0.85–1.81) | 1.09 (0.75–1.59) |
| ucOC/TOC Q1 | 22.1–49.0 | 66 (12.5) | 1.00 | ||||
| ucOC/TOC Q2–4 | 49.0–87.3 | 118 (7.8) | 0.61 (0.45–0.82) | 0.69 (0.51–0.94) | 0.67 (0.50–0.92) | 0.62 (0.45–0.84) | 0.70 (0.51–0.97) |
| P1NP (μg/L) Q1 | 9.5–28.2 | 30 (6.3) | 1.00 | ||||
| P1NP (μg/liter) Q2–4 | 28.2–710.1 | 154 (9.8) | 1.57 (1.06–2.32) | 1.46 (0.99–2.16) | 1.48 (0.99–2.20) | 1.56 (1.05–2.34) | 1.43 (0.95–2.15) |
| CTX (μg/L) Q1 | 0.1–0.2 | 36 (8.0) | |||||
| CTX (μg/L) Q2—4 | 0.2–2.5 | 148 (9.3) | 1.19 (0.83–1.71) | 1.03 (0.71–1.48) | 1.01 (0.70–1.46) | 1.18 (0.82–1.72) | 0.98 (0.67–1.43) |
Proportional hazards regression of total OC, ucOC, ucOC/total OC, P1NP, and CTX for the outcome of nonfatal and fatal MI, after excluding men with metabolic syndrome at baseline (n = 1186). Metabolic syndrome was defined according to the National Cholesterol Education Program-Adult Treatment Panel classification as three or more of waist circumference >102 cm, fasting plasma glucose ≥5.6 mmol/liter, or a known diagnosis of diabetes, fasting triglycerides ≥1.7 mmol/liter, fasting high-density lipoprotein cholesterol <1.03 mmol/liter, or blood pressure ≥130/85 mm Hg. Men with a previous diagnosis of hypertension or taking antihypertensive therapy were regarded as fulfilling the criterion for hypertension. Results are shown for men in the highest three quartiles compared with men in the lowest quartile (Q2–4 versus reference Q1).
Model 1: adjusted for age.
Model 2: adjustment as in model 1 and for education, smoking, BMI, and WHR.
Model 3: adjustment as in model 2 and for hypertension, dyslipidemia, diabetes, creatinine, and vitamin D.
Model 4: adjustment as in model 3 and for prevalent CVD and cancer.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
